Dr. Oliver Dimitrijevic, MD

Dr. Dimitrijevic practices at St. Mark's Hospital in Salt Lake City, Utah, part of HCA Healthcare.

Dr. Dimitrijevic's NPI, 1003055252, was assigned on February 11, 2009. Dr. Dimitrijevic holds Michigan license 4301089472.

Dr. Dimitrijevic's primary practice is St. Mark's Hospital, at 1200 East 3900 South, Salt Lake City, UT 84124 in Salt Lake County. The practice phone is (801) 268-7111.

Dr. Dimitrijevic's primary practice is St. Mark's Hospital in Salt Lake City, Utah, part of HCA Healthcare. Dr. Dimitrijevic is also affiliated with UCHealth Parkview Medical Center. The medical group on file is Intermountain Health. Dmand AI also links Dr. Dimitrijevic to 4 more hospitals, 12 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dimitrijevic practices, 7 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Dimitrijevic's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Dimitrijevic is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Dimitrijevic's licenses on file in 2 states: Michigan and Indiana.

CMS data shows 976 Medicare services from Dr. Dimitrijevic across 5 procedure codes in 2024, for 302 Medicare patients. Medicare paid $63,170 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 302 Medicare patients who saw Dr. Dimitrijevic in 2024. The largest group is 65 to 74, with 111 patients. 75% of them have high blood pressure, and 65% have high cholesterol. 26% are also on Medicaid. Their average risk score is 2.10, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dimitrijevic's median patient age at 68, with 46% women.

In 2024, Dr. Dimitrijevic wrote 294 Medicare Part D claims for 141 patients. 79% of them were for generic drugs. CMS names the drug for 92 of them, across 4 drugs with 11 or more claims each, at $10,737 in total drug cost. In 2023, CMS named 121 claims across 6 drugs.

Dr. Dimitrijevic accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Dimitrijevic to 10 clinical trials, 4 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Adenocarcinoma of Lung, Biliary Atresia and Low Back Pain.

CMS Open Payments shows 5 general payments to Dr. Dimitrijevic from 4 drug and device companies from 2016 to 2020. Food and beverage make up the largest share, 100% of the total. Bristol-Myers Squibb Company paid the most, $27.